Literature DB >> 31634201

T cells with high PD-1 expression are associated with lower HIV-specific immune responses despite long-term antiretroviral therapy.

Bernard J C Macatangay1, Rajesh T Gandhi, Richard B Jones, Deborah K Mcmahon, Christina M Lalama, Ronald J Bosch, Joshua C Cyktor, Allison S Thomas, Luann Borowski, Sharon A Riddler, Evelyn Hogg, Eva Stevenson, Joseph J Eron, John W Mellors, Charles R Rinaldo.   

Abstract

OBJECTIVE: We evaluated frequencies of T cells with high PD-1 expression (PD-1) before and after long-term effective antiretroviral therapy (ART), and determined if frequencies on-ART correlated positively with measures of HIV persistence and negatively with HIV-specific responses.
METHODS: We enrolled individuals who started ART during chronic infection and had durable suppression of viremia for at least 4 years (N = 99). We assessed PD-1 T-cell frequencies at timepoints pre-ART and on-ART using flow cytometry, and evaluated how frequencies on-ART are associated with measures of HIV persistence, HIV-specific immune responses, and immune activation levels.
RESULTS: Pre-ART, PD-1 CD4 T cells correlated positively with viremia and negatively with CD4 T-cell count. At year 1 on-ART, %PD-1 CD4 T cells decreased but then remained stable at 4 and 6-15 years on-ART, whereas %PD-1 CD8 T cells on-ART remained similar to pre-ART. PD-1 CD4 T cells correlated positively with HIV DNA pre-ART and on-ART, and with CD4 T-cell activation on-ART. PD-1 CD4 T cells negatively correlated with HIV Gag-specific and Env-specific T-cell responses but not with CMV-specific or EBV-specific responses. PD-1 CD8 T cells trended towards a negative correlation with responses to Gag and Env, but not to CMV and EBV.
CONCLUSION: PD-1 T cells persist in blood despite prolonged suppression on ART, correlate with HIV DNA levels, and are associated with lower HIV-specific T-cell responses but not CMV-specific or EBV-specific responses, suggesting that these cells are HIV-specific. The findings support evaluating PD-1 blockade strategies for their effect on HIV persistence and HIV-specific immunity.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31634201      PMCID: PMC7313719          DOI: 10.1097/QAD.0000000000002406

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.632


  40 in total

1.  PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors.

Authors:  Ji-Yuan Zhang; Zheng Zhang; Xicheng Wang; Jun-Liang Fu; Jinxia Yao; Yanmei Jiao; Liangen Chen; Hui Zhang; Jianan Wei; Lei Jin; Ming Shi; George Fu Gao; Hao Wu; Fu-Sheng Wang
Journal:  Blood       Date:  2007-02-01       Impact factor: 22.113

Review 2.  CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer.

Authors:  Laura M McLane; Mohamed S Abdel-Hakeem; E John Wherry
Journal:  Annu Rev Immunol       Date:  2019-01-24       Impact factor: 28.527

Review 3.  T cell exhaustion during persistent viral infections.

Authors:  Shannon M Kahan; E John Wherry; Allan J Zajac
Journal:  Virology       Date:  2015-01-22       Impact factor: 3.616

Review 4.  Clonal Expansion of Human Immunodeficiency Virus-Infected Cells and Human Immunodeficiency Virus Persistence During Antiretroviral Therapy.

Authors:  James I Mullins; Lisa M Frenkel
Journal:  J Infect Dis       Date:  2017-03-15       Impact factor: 5.226

5.  Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment.

Authors:  E John Wherry; Joseph N Blattman; Kaja Murali-Krishna; Robbert van der Most; Rafi Ahmed
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

6.  Restoring function in exhausted CD8 T cells during chronic viral infection.

Authors:  Daniel L Barber; E John Wherry; David Masopust; Baogong Zhu; James P Allison; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Nature       Date:  2005-12-28       Impact factor: 49.962

7.  Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells.

Authors:  Hiroyu Hatano; Vivek Jain; Peter W Hunt; Tzong-Hae Lee; Elizabeth Sinclair; Tri D Do; Rebecca Hoh; Jeffrey N Martin; Joseph M McCune; Frederick Hecht; Michael P Busch; Steven G Deeks
Journal:  J Infect Dis       Date:  2012-10-22       Impact factor: 5.226

8.  High production rates sustain in vivo levels of PD-1high simian immunodeficiency virus-specific CD8 T cells in the face of rapid clearance.

Authors:  Constantinos Petrovas; Takuya Yamamoto; David A Price; Srinivas S Rao; Nichole R Klatt; Jason M Brenchley; Daniel C Douek; Emma Gostick; Bastian R Angermann; Zvi Grossman; Derek C Macallan; Martin Meier-Schellersheim; Richard A Koup
Journal:  J Virol       Date:  2013-07-03       Impact factor: 5.103

Review 9.  Immune Exhaustion: Past Lessons and New Insights from Lymphocytic Choriomeningitis Virus.

Authors:  Shannon M Kahan; Allan J Zajac
Journal:  Viruses       Date:  2019-02-13       Impact factor: 5.048

10.  Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Authors:  Y Ishida; Y Agata; K Shibahara; T Honjo
Journal:  EMBO J       Date:  1992-11       Impact factor: 11.598

View more
  11 in total

Review 1.  Insights Into Persistent HIV-1 Infection and Functional Cure: Novel Capabilities and Strategies.

Authors:  Tram M Ta; Sajjaf Malik; Elizabeth M Anderson; Amber D Jones; Jocelyn Perchik; Maryann Freylikh; Luca Sardo; Zackary A Klase; Taisuke Izumi
Journal:  Front Microbiol       Date:  2022-04-27       Impact factor: 6.064

2.  T cell immune discriminants of HIV reservoir size in a pediatric cohort of perinatally infected individuals.

Authors:  Stefano Rinaldi; Lesley de Armas; Sara Dominguez-Rodríguez; Suresh Pallikkuth; Vinh Dinh; Li Pan; Kathleen Gӓrtner; Rajendra Pahwa; Nicola Cotugno; Pablo Rojo; Eleni Nastouli; Nigel Klein; Caroline Foster; Anita De Rossi; Carlo Giaquinto; Paolo Rossi; Paolo Palma; Savita Pahwa
Journal:  PLoS Pathog       Date:  2021-04-26       Impact factor: 6.823

3.  Suspected Immune-Related Adverse Events With an Anti-PD-1 Inhibitor in Otherwise Healthy People With HIV.

Authors:  Cynthia L Gay; Ronald J Bosch; Ashley McKhann; Kendall F Moseley; Chanelle L Wimbish; Steven M Hendrickx; Michael Messer; Maureen Furlong; Danielle M Campbell; Cheryl Jennings; Constance Benson; Edgar T Overton; Bernard J C Macatangay; Daniel R Kuritzkes; Elizabeth Miller; Randall Tressler; Joseph J Eron; William David Hardy
Journal:  J Acquir Immune Defic Syndr       Date:  2021-08-15       Impact factor: 3.771

4.  Association of Male Sex and Obesity With Residual Plasma Human Immunodeficiency Virus 1 Viremia in Persons on Long-Term Antiretroviral Therapy.

Authors:  Joshua C Cyktor; Ronald J Bosch; Hanna Mar; Bernard J Macatangay; Ann C Collier; Evelyn Hogg; Catherine Godfrey; Joseph J Eron; Deborah K McMahon; John W Mellors; Rajesh T Gandhi
Journal:  J Infect Dis       Date:  2021-02-13       Impact factor: 7.759

Review 5.  Systemic Inflammation Associated with Immune Reconstitution Inflammatory Syndrome in Persons Living with HIV.

Authors:  Caian L Vinhaes; Mariana Araujo-Pereira; Rafael Tibúrcio; Juan M Cubillos-Angulo; Fernanda O Demitto; Kevan M Akrami; Bruno B Andrade
Journal:  Life (Basel)       Date:  2021-01-18

Review 6.  Immune checkpoint blockade in HIV.

Authors:  Celine Gubser; Chris Chiu; Sharon R Lewin; Thomas A Rasmussen
Journal:  EBioMedicine       Date:  2022-02-02       Impact factor: 8.143

7.  Global transcriptomic characterization of T cells in individuals with chronic HIV-1 infection.

Authors:  Xiang-Ming Wang; Ji-Yuan Zhang; Xudong Xing; Hui-Huang Huang; Peng Xia; Xiao-Peng Dai; Wei Hu; Chao Zhang; Jin-Wen Song; Xing Fan; Feng-Ying Wu; Fu-Hua Liu; Yuehua Ke; Yifan Zhao; Tian-Jun Jiang; Li-Feng Wang; Yan-Mei Jiao; Ruo-Nan Xu; Lei Jin; Ming Shi; Fan Bai; Fu-Sheng Wang
Journal:  Cell Discov       Date:  2022-03-28       Impact factor: 10.849

8.  Impact of Anti-PD-1 and Anti-CTLA-4 on the Human Immunodeficiency Virus (HIV) Reservoir in People Living With HIV With Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study.

Authors:  Thomas A Rasmussen; Lakshmi Rajdev; Ajantha Rhodes; Ashanti Dantanarayana; Surekha Tennakoon; Socheata Chea; Tim Spelman; Shelly Lensing; Rachel Rutishauser; Sonia Bakkour; Michael Busch; Janet D Siliciano; Robert F Siliciano; Mark H Einstein; Dirk P Dittmer; Elizabeth Chiao; Steven G Deeks; Christine Durand; Sharon R Lewin
Journal:  Clin Infect Dis       Date:  2021-10-05       Impact factor: 9.079

9.  Antiretroviral therapy does not reduce tuberculosis reactivation in a tuberculosis-HIV coinfection model.

Authors:  Shashank R Ganatra; Allison N Bucşan; Xavier Alvarez; Shyamesh Kumar; Ayan Chatterjee; Melanie Quezada; Abigail Fish; Dhiraj K Singh; Bindu Singh; Riti Sharan; Tae-Hyung Lee; Uma Shanmugasundaram; Vijayakumar Velu; Shabaana A Khader; Smriti Mehra; Jyothi Rengarajan; Deepak Kaushal
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 19.456

Review 10.  Expression Profile and Biological Role of Immune Checkpoints in Disease Progression of HIV/SIV Infection.

Authors:  Yuting Sun; Jing Xue
Journal:  Viruses       Date:  2022-03-11       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.